How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Infectious Disease Archives

3 Deaths and 17 Illnesses Tied to Listeria Outbreak From Recalled Chicken Alfredo Meals

Bloodstream Infections in Ethiopia Reveal High Rates of Multidrug Resistance and Fungal Involvement

Considering the Impact of Crop Spraying and Antifungal Resistance

Outpatient C difficile Cases Reveal Diagnostic Gaps and PPI-Linked Risks

Diagnostic Stewardship or Laboratory Retrogress?

Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV

FDA Approves Gilead’s Twice-Yearly Injectable Yeztugo (Lenacapavir) for HIV Prevention

30% of Americans Express Vaccine Skepticism

Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections

Geographic And Demographic Variations in Hepatitis C Mortality

Schedule an Appointment

Quick Links

Patient Forms

Contact Us